On April 27:
They have endorsed the work with Omnicare of Philadelphia on the details of the clinical trials.
On the June 2:
They announced that the company has signed a contract with a FDA approved, GMP licensed phamaceutical manufacturing company, Confab, for the production of X-Excite.
On the June 22:
The company announced that it has completed the clinical trials, a PK study in Europe under EMEA guide line. The company reported details of the trial, and it said the trial provided the expected and successful end point.
On the July 6:
They announced it has appointed Dr. Lola Maksumova,MD,PhD as senior VP and Chief Operating Officer mainly for the third party contract research organization and FDA.
On the July 16:
They announced that they have secured finance for the projects.
This stock will soar. Buy it while you can at this price.
